Molecular Tests Evaluated for Clostridium difficile Identification
By LabMedica International staff writers Posted on 21 Jul 2015 |
Two commercial isothermal amplification assays have been compared for the detection of Clostridium difficile toxin in fresh fecal samples from adult and pediatric patients.
Laboratory diagnosis of C. difficile is routinely accomplished by the detection of produced toxins, detection of toxin genes, or a two-step approach where the detection of a C. difficile–specific antigen, glutamate dehydrogenase, is followed by detection of toxins or toxin genes.
Laboratory scientists at the Nationwide Children's Hospital (Columbus, OH, USA) and their colleagues collected a total of 758 fresh stool specimens, liquid or soft, submitted for C. difficile testing as part of routine patient care from January 2013 till September 2013. There were no age restrictions on the patient specimens. Inclusion criteria were an order of C. difficile testing as part of standard of care testing for patients with symptoms of diarrhea.
All stool samples were tested for the presence of C. difficile toxin gene using the Illumigene assay (Meridian Biosciences; Cincinnati, OH, USA). Fifty microliters of the treated sample was added to the reaction buffer and placed into the Meridian Biosciences’ illumipro-10 instrument where isothermal amplification and detection was performed. Remnant stool specimens from patients that were enrolled in the study were deidentified and tested by the AmpliVue assay (Quidel; San Diego, CA, USA). Any discordant results were resolved by performing toxigenic culture.
The AmpliVue C. difficile assay showed 97.8% concordance with the Illumigene assay. Among all three sites where the study was performed, there were 16 discrepant results that were resolved by performing cytotoxigenic culture in these samples. Following discordant resolution, the combined performance for all three sites for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for AmpliVue was 96.1%, 99.2%, 96.1%, and 99.2%, respectively, while for Illumigene was 96.1%, 99.8%, 99.2%, and 99.2%, respectively.
The authors concluded that both AmpliVue and Illumigene C. difficile assays can be used in diverse laboratory settings with both adult and pediatric patient populations. They can reliably detect the presence or absence of C. difficile toxin genes in stool samples, providing fast results for the proper treatment of patients and initiation of infection control measures. The study was published in the August 2015 issue of the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Nationwide Children's Hospital
Meridian Biosciences
Quidel
Laboratory diagnosis of C. difficile is routinely accomplished by the detection of produced toxins, detection of toxin genes, or a two-step approach where the detection of a C. difficile–specific antigen, glutamate dehydrogenase, is followed by detection of toxins or toxin genes.
Laboratory scientists at the Nationwide Children's Hospital (Columbus, OH, USA) and their colleagues collected a total of 758 fresh stool specimens, liquid or soft, submitted for C. difficile testing as part of routine patient care from January 2013 till September 2013. There were no age restrictions on the patient specimens. Inclusion criteria were an order of C. difficile testing as part of standard of care testing for patients with symptoms of diarrhea.
All stool samples were tested for the presence of C. difficile toxin gene using the Illumigene assay (Meridian Biosciences; Cincinnati, OH, USA). Fifty microliters of the treated sample was added to the reaction buffer and placed into the Meridian Biosciences’ illumipro-10 instrument where isothermal amplification and detection was performed. Remnant stool specimens from patients that were enrolled in the study were deidentified and tested by the AmpliVue assay (Quidel; San Diego, CA, USA). Any discordant results were resolved by performing toxigenic culture.
The AmpliVue C. difficile assay showed 97.8% concordance with the Illumigene assay. Among all three sites where the study was performed, there were 16 discrepant results that were resolved by performing cytotoxigenic culture in these samples. Following discordant resolution, the combined performance for all three sites for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for AmpliVue was 96.1%, 99.2%, 96.1%, and 99.2%, respectively, while for Illumigene was 96.1%, 99.8%, 99.2%, and 99.2%, respectively.
The authors concluded that both AmpliVue and Illumigene C. difficile assays can be used in diverse laboratory settings with both adult and pediatric patient populations. They can reliably detect the presence or absence of C. difficile toxin genes in stool samples, providing fast results for the proper treatment of patients and initiation of infection control measures. The study was published in the August 2015 issue of the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Nationwide Children's Hospital
Meridian Biosciences
Quidel
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia